Journal Article

Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity

W. Hiatt

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 4, issue suppl_B, pages B50-B54
Published in print March 2002 | ISSN: 1520-765X
Published online March 2002 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(02)90018-0
Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity

Show Summary Details

Preview

Peripheral arterial disease (PAD) is among the common manifestations of systemic atherosclerosis. In the U.S.A. it is estimated that this disorder affects 8–10 million adults, with resultant increased risk for cardiovascular morbidity and mortality. Thus, 50% of patients with PAD will have a fatal or non-fatal cardiovascular event within 5 years. The initial treatment goal in patients with PAD is to identify their risk factors for atherosclerosis and then to initiate risk factor modification. These patients should all be placed on antiplatelet therapy as well. However, these interventions typically do not result in an immediate change in the symptoms of PAD, mainly intermittent claudication, and additional interventions are necessary to treat this disabling symptom. These include a formal exercise programme; with regard to pharmacological therapies cilostizol is available in the U.S.A., and several medications that are effective including propionyl-l- carnitine are available in Europe.

Keywords: Intermittent claudication; peripheral arterial disease

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.